Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: PakisztánFázis nélkül

Role of Vitamin D Supplementation in Children With Irritable Bowel Syndrome

A legfontosabb adatok

Ki végzi
Aziz Bhatti Shaheed Teaching Hospital
Hol
Gujrat (Pakisztán)A helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
48 fő, tervezett
Kezdés
2026. szept. 1.
Várható befejezés
2027. márc. 30.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Vitamin D3
  • Placebo
A regiszteradat frissítve
2026. november 3.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for children with irritable bowel syndrome (IBS) and low vitamin D levels. It tests whether vitamin D3 drops ease their symptoms compared with dummy drops.

Életkor
6 to 14 years
Nem
Boys and girls
A betegség stádiuma
IBS diagnosed by the Rome IV criteria, any subtype (with constipation, with diarrhea, mixed or unsubtyped). Symptoms for at least 2 months before joining.
Korábbi kezelés
No vitamin D, calcium or multivitamins with vitamin D in the last 8 weeks. Also no corticosteroids, anticonvulsants, rifampicin or other drugs affecting vitamin D in that time.
Biomarker vagy leletérték
Blood 25-hydroxyvitamin D level between 10 and 29 ng/mL.

A részvétel fő kizáró okai

  • Normal or sufficient vitamin D level
  • Other bowel or digestive diseases, such as inflammatory bowel disease, celiac disease or liver disease
  • Warning signs such as weight loss, poor growth, fever, bleeding from the gut or unexplained anemia
  • Long-term illness affecting vitamin D or the gut, such as kidney disease or hormone disorders
  • Major abdominal surgery affecting the bowel, or a current gut infection

A regiszter feltételei, szó szerint

Mind a 15 feltétel megnézéseKevesebb

Ki vehet részt

  • Children aged 6 to 14 years of either gender
  • Children diagnosed with irritable bowel syndrome according to Rome IV criteria as per operational definition
  • Children belonging to any irritable bowel syndrome subtype, including IBS with constipation, IBS with diarrhea, mixed IBS, and unsubtyped IBS
  • Children with serum 25-hydroxyvitamin D levels between 10 and 29 ng/mL, including vitamin D deficiency defined as 10-19 ng/mL and vitamin D insufficiency defined as 20-29 ng/mL
  • Children with symptoms present for at least 2 months prior to enrollment
  • Children who are able to take oral vitamin D supplementation and attend follow-up visits
  • Children whose parents or legal guardians provide written informed consent, with assent from the child where appropriate

Ki nem vehet részt

  • Children with evidence of organic gastrointestinal disease, including inflammatory bowel disease, celiac disease, peptic ulcer disease, gastrointestinal tuberculosis, chronic liver disease, pancreatic disease, intestinal obstruction, Hirschsprung disease, or gastrointestinal malignancy
  • Children having alarm features suggestive of organic pathology, including: unintentional weight loss, growth failure or short stature, persistent fever, gastrointestinal bleeding, including hematemesis, melena, or blood in stool, chronic severe diarrhea, unexplained anemia, organomegaly
  • Children with chronic systemic illness that may affect vitamin D metabolism or gastrointestinal symptoms, including chronic kidney disease, nephrotic syndrome, hyperparathyroidism, malabsorption syndrome, metabolic bone disease, or endocrine disorders
  • Children with acute gastrointestinal infection at the time of assessment
  • Children with severe neurodevelopmental, psychiatric, or communication disorders making reliable symptom assessment difficult
  • Children with a history of major abdominal surgery likely to affect bowel function
  • Children receiving vitamin D supplements, calcium supplements, multivitamins containing vitamin D, corticosteroids, anticonvulsants, rifampicin, or other drugs affecting vitamin D metabolism within the last 8 weeks
  • Children with vitamin D deficiency or normal/sufficient vitamin D level

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 6 és 14 év között vagy?

Helyszínek itt: Pakisztán

  • Aziz Bhatti Shaheed Teaching HospitalGujrat, PakisztánContact: Imaan TahirRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study was designed to determine whether vitamin D supplementation improved symptoms in children with irritable bowel syndrome, a condition associated with repeated abdominal pain and changes in bowel habits. It was hypothesized that vitamin D supplementation would reduce symptom severity and increase blood vitamin D levels compared with placebo.

A teljes eredeti leírásKevesebb

The study was a randomized, placebo-controlled trial at the Department of Pediatrics, Aziz Bhatti Shaheed Teaching Hospital, Gujrat, Pakistan. It included 60 children aged 6-14 years who met established diagnostic criteria for irritable bowel syndrome and had low blood vitamin D levels of 10-29 ng/mL. Children were randomly assigned to two groups of 30 participants each. One group received oral vitamin D3 drops containing 2,000 international units once daily for 12 weeks. The other group received matching placebo drops without vitamin D for the same period. Both groups received routine supportive care, including advice on hydration, regular meals, diet, and symptom management.

Follow-up visits were scheduled at 4, 8, and 12 weeks to assess symptoms, treatment adherence, and possible side effects. The main outcome was the change in symptom severity from the start of treatment to 12 weeks, measured using a standardized symptom score. The secondary outcome was the change in blood vitamin D levels over the same period. Changes in both outcomes were compared between the two groups.

A vizsgálat 2 csoportja

  • Group A - Vitamin D3A vizsgált kezelés

    Participants received oral vitamin D3 drops containing 2,000 international units once daily for 12 weeks, alongside standard supportive care for irritable bowel syndrome.

    Kezelés: Vitamin D3

  • Group B - PlaceboPlacebo, összehasonlításként

    Participants received matching placebo drops orally once daily for 12 weeks, alongside standard supportive care for irritable bowel syndrome.

    Kezelés: Placebo

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Role of Vitamin D Supplementation in Children With Irritable Bowel Syndrome: A Randomized Controlled Trial
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT07914478: ki vehet részt
A regiszteradat frissítve
2026. november 3.